Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer

Pharmaceutical Research

Volumn 25, Issue 2, 2008, Pages 400-406

  Zhang, Yun ^a   Wang, Yuntao ^a   Boado, Ruben J ^a   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Liposomes; Lysosomal storage disorders; Transferrin receptor

Indexed keywords

BETA GLUCURONIDASE; LIPOSOME; LYSOSOME ENZYME; MONOCLONAL ANTIBODY; PLASMID DNA; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG PENETRATION; ENZYME ACTIVITY; ENZYME REPLACEMENT; EXPERIMENTAL MOUSE; FIBROBLAST CULTURE; HORSE; KIDNEY; LIVER; LUNG; MALE; MOUSE; MUCOPOLYSACCHARIDOSIS; MUCOPOLYSACCHARIDOSIS 7; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN;

ANIMALS; BRAIN; CERCOPITHECUS AETHIOPS; COS CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLUCURONIDASE; HUMANS; LYSOSOMES; MALE; MICE; MICE, INBRED BALB C; PLASMIDS;

EID: 39149083089     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9357-6     Document Type: Article

References (34)

1. Y. A. Ioannou. Gene therapy for lysosomal storage disorders with neuropathology. J. Am. Soc. Nephrol. 11:1542-1547 (2000).
2. C. Martini, G. Ciana, A. Benettoni, F. Katouzian, G. M. Severini, R. Bussani, et al. Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology 57:906-908 (2001).
3. S. S. Elliger, C. A. Elliger, C. P. Aguilar, N. R. Raju, and G. L. Watson. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther. 6:1175-1178 (1999).
4. L. Xu, R. L. Mango, M. S. Sands, M. E. Haskins, N. M. Ellinwood, and K. P. Ponder. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol. Ther. 6:745-758 (2002).
5. M. A. Passini and J. H. Wolfe. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J. Virol. 75:12382-12392 (2001).
6. B. A. Karolewski and J. H. Wolfe. Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol. Ther. 14:14-24 (2006).
7. A. F. Skorupa, K. J. Fisher, J. M. Wilson, M. K. Parente, and J. H. Wolfe. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp. Neurol. 160:17-27 (1999).
8. C. H. Vite, M. A. Passini, M. E. Haskins, and J. H. Wolfe. Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. 10:1874-1881 (2003).
9. W. M. Pardridge. Drug and gene delivery to the brain: the vascular route. Neuron 36:555-558 (2002).
10. N. Shi, Y. Zhang, C. Zhu, R. J. Boado, and W. M. Pardridge. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U.S.A. 98:12754-12759 (2001).
11. N. Shi, R. J. Boado, and W. M. Pardridge. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18:1091-1095 (2001).
12. Y. Zhang, F. Schlachetzki, and W.M. Pardridge. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7:11-18 (2003).
13. D. C. Mash, J. Pablo, D. D. Flynn, S. M. Efange, and W. J. Weiner. Characterization and distribution of transferrin receptors in the rat brain. J. Neurochem. 55:1972-1979 (1990).
14. W. Zhao, H. Chen, H. Xu, E. Moore, N. Meiri, M. J. Quon, et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 274:34893-34902 (1999).
15. E. H. Birkenmeier, M. T. Davisson, W. G. Beamer, R. E. Ganschow, C. A. Vogler, B. Gwynn, et al. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J. Clin. Invest. 83:1258-1266 (1989).
16. J. W. Kyle, E. H. Birkenmeier, B. Gwynn, C. Vogler, P. C. Hoppe, J. W. Hoffmann, et al. Correction of murine mucopolysaccharidosis VII by a human beta-glucuronidase transgene. Proc. Natl. Acad. Sci. U.S.A. 87:3914-3918 (1990).
17. R. J. Boado, J. Y. Li, M. Nagaya, C. Zhang, and W. M. Pardridge. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 96:12079-12084 (1999).
18. R. J. Boado, J. Y. Li, C. Chu, F. Ogoshi, P. Wise, and W. M. Pardridge. Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. Biochim. Biophys. Acta 1715:104-110 (2005).
19. W. M. Pardridge. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol. 373:507-528 (2003).
20. Y. Zhang, R. J. Boado, and W. M. Pardridge. Marked enhancement in gene expression by targeting the human insulin receptor. J. Genet. Med. 5:157-163 (2003).
21. M. R. Islam, J. H. Grubb, and W. S. Sly. C-terminal processing of human beta-glucuronidase. The propeptide is required for full expression of catalytic activity, intracellular retention, and proper phosphorylation. J. Biol. Chem. 268:22627-22633 (1993).
22. J. H. Wolfe, J. W. Kyle, M. S. Sands, W. S. Sly, D. G. Markowitz, and M. K. Parente. High level expression and export of beta-glucuronidase from murine mucopolysaccharidosis VII cells corrected by a double-copy retrovirus vector. Gene Ther. 2:70-78 (1995).
23. M. R. Islam, S. Tomatsu, G. N. Shah, J. H. Grubb, S. Jain, and W. S. Sly. Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. J. Biol. Chem. 274:23451-23455 (1999).
24. J. Jakobsson, C. Ericson, M. Jansson, E. Bjork, and C. Lundberg. Targeted transgene expression in rat brain using lentiviral vectors. J. Neurosci. Res. 73:876-885 (2003).
25. B. J. Wu, S. Tomatsu, S. Fukuda, K. Sukegawa, T. Orii, and W. S. Sly. Overexpression rescues the mutant phenotype of L176F mutation causing β-glucuronidase deficiency mucopolysaccharidosis in two Mennonite siblings. J. Biol. Chem. 269:23681-23688 (1994).
26. N. Shi, and W. M. Pardridge. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. U.S.A. 97:7567-7572 (2000).
27. S. Skarlatos, and W. M. Pardridge. Targeting of an anti-CR3 (CD11b/CD18) monoclonal antibody to spleen, but not brain, in vivo in mice. J. Drug Target. 3:9-14 (1995).
28. G. Liu, I. Martins, J. A. Wemmie, J. A. Chiorini, and B. L. Davidson. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. 25:9321-9327 (2005).
29. A. Bosch, E. Perret, N. Desmaris, D. Trono, and J. M. Heard. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11:1139-1150 (2000).
30. B. K. Berges, J. H. Wolfe, and N. W. Fraser. Stable levels of long-term transgene expression driven by the latency-associated transcript promoter in a herpes simplex virus type 1 vector. Mol. Ther. 12:1111-1119 (2005).
31. M. S. Sands, C. A. Vogler, K. K. Ohlemiller, M. S. Roberts, J. H. Grubb, B. Levy, et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J. Biol. Chem. 276:43160-43165 (2001).
32. A. Urayama, J. H. Grubb, W. S. Sly, and W. A. Banks. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 101:12658-12663 (2004).
33. C. Vogler, N. Galvin, B. Levy, J. Grubb, J. Jiang, X. Y. Zhou, and W. S Sly. Transgene produces massive overexpression of human beta-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc. Natl. Acad. Sci. U.S.A. 100:2669-2673 (2003).
34. C. Chu, Y. Zhang, R. J. Boado, and W. M. Pardridge. Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation. Pharm. Res. 23:1586-1590 (2006).